Sweden: Lindberg replaces Duvall as CEO at Oncopeptides following withdrawal of Pepaxto from US

Oncopeptides, a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has appointed Jakob Lindberg as CEO of Oncopeptides. Effective immediately, Lindberg replaces Marty J Duvall, who has been CEO since July 1, 2020. The leadership change follows the withdrawal of Pepaxto (INN melphalan flufenamide) from the US market and the…

You must be a HMI Subscriber to view this content.

Login » Subscribe Now »

Advertisement